Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
BGLC
#8992
BioNexus Gene Lab Corp Common stock
2.265
0
USD
-2.37%
Sektor:
Grundstoffe
Basis:
USD
Gewinnwährung:
USD
Tagesspanne
Jahresspanne
Tagesänderung
-2.37%
Monatliche Änderung
+0.89%
6 month change
+0.89%
Jahresänderung
+0.89%
Vorheriger Schlusskurs
2.320
0
Open
2.236
0
Bid
2.265
0
Ask
2.268
0
Low
2.230
0
High
2.299
9
Volumen
7
Märkte
Aktien
Grundstoffe
BGLC
Open full chart
Financials
Overview
Finanzbericht
Statistics
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
1.8 M
17.97 M
1.8 M
1.8 M
1.8 M
—
Valuation ratios
Enterprise value
—
—
—
5.52 M
9.83 M
—
Price to earnings ratio
—
—
—
—
-24.75
—
Price to sales ratio
—
—
—
—
1.86
—
Price to cash flow ratio
—
—
—
—
-4.79
—
Price to book ratio
—
—
—
—
0.62
—
Enterprise value to EBITDA ratio
—
—
—
0.86
1.85
—
Profitability ratios
Return on assets %
-0.12
-0.03
-0.07
-0.07
-0.09
-0.26
Return on equity %
-0.14
-0.04
-0.08
-0.08
-0.1
-0.31
Return on invested capital %
-67.8
-19.74
-34
—
—
—
Gross margin %
12.41
12.25
16.07
16.28
14.85
59.45
Operating margin %
-50.85
-16.49
-28.94
-27.05
-27.62
-100.09
EBITDA margin %
-67.25
298.41
68.48
-35.08
-113.53
218.28
Net margin %
-51.15
-13.8
-29.17
-27.26
-27.87
-98.1
Liquidity ratios
Quick ratio
3.99
3.1
3.44
2.94
6.81
16.28
Current ratio
4.98
3.81
4.19
3.63
8.3
19.93
Inventory turnover
—
0.03
0.01
0.01
0.02
0.08
Asset turnover
0.24
0.24
0.21
0.24
0.3
0.99
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
0
-0.05
-0.41
-0.69
-1.14
EBIT per share
—
0.42
0.08
-0.46
-0.45
-0.41
EBITDA per share
—
0.42
0.08
-0.44
-1.61
-1.54
Total debt per share
—
—
—
—
—
—
Cash per share
—
0.09
0.06
—
—
—
Net current asset value per share
—
0.42
0.36
3.55
3.13
7.46
Tangible book value per share
—
0.47
0.43
4.19
3.79
8.88
Working capital per share
—
0.31
0.28
2.57
2.75
5.91
Book value per share
—
0.47
0.43
4.19
3.79
8.88
Nachrichten
BioNexus Gene Lab appoints commercial officer at Fidelion
BioNexus Gene Lab schließt strategische Transaktion mit Fidelion Diagnostics ab
BioNexus Gene Lab completes strategic deal with Fidelion Diagnostics
BioNexus-Aktie gibt nach Sicherung einer 500-Millionen-Dollar-Finanzierung nach
BioNexus Gene Lab stock falls after securing $500M equity facility
BioNexus Gene Lab secures $500 million equity purchase agreement
BioNexus-Aktie steigt nach Sicherung einer Eigenkapitalfazilität über 500 Millionen US-Dollar
BioNexus Gene Lab stock climbs after securing $500 million equity facility
BioNexus-Aktie schießt nach strategischen Vereinbarungen für MRD-Tests in die Höhe
BioNexus Gene Lab forms partnership to commercialize liquid biopsy platform
BioNexus Gene Lab stock soars after strategic MRD testing agreements
BioNexus Gene Lab files $100 million shelf registration, launches ATM program